Journal Article

Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials

Hopkins, Ashley M, Li, Lee X, Socinski, Mark A, Cappuzzo, Federico, Matos, Ignacio, Sorich, Michael J

2023

Overview

Abstract Background Monotherapy immune checkpoint inhibitor (ICI) used in second- or later-line settings has been reported to induce hyperprogression. This study evaluated hyperprogression risk with ICI (atezolizumab) in the first-, second-, or later-line treatment of advanced non–small cell lung cancer (NSCLC), and provides insights into hyperprogression risk with contemporary first-line ICI treatment. Methods Hyperprogression was identified using Response Evaluation Criteria in Solid Tumours (RECIST)-based criteria in a dataset of pooled individual-participant level data from BIRCH, FIR, IMpower130, IMpower131, IMpower150, OAK, and POPLAR trials. Odds ratios were computed to compare hyperprogression risks between groups. Landmark Cox proportional-hazard regression was used to evaluate the association between hyperprogression and progression-free survival/overall survival. Secondarily, putative risk factors for hyperprogression among second- or later-line atezolizumab-treated patients were evaluated using univariate logistic regression models. Results Of the included 4644 patients, 119 of the atezolizumab-treated patients (n = 3129) experienced hyperprogression. Hyperprogression risk was markedly lower with first-line atezolizumab—either chemoimmunotherapy or monotherapy—compared to second/later-line atezolizumab monotherapy (0.7% vs. 8.8%, OR = 0.07, 95% CI, 0.04-0.13). Further, there was no statistically significant difference in hyperprogression risk with first-line atezolizumab-chemoimmunotherapy versus chemotherapy alone (0.6% vs. 1.0%, OR = 0.55, 95% CI, 0.22-1.36). Sensitivity analyses using an extended RECIST-based criteria including early death supported these findings. Hyperprogression was associated with worsened overall survival (HR = 3.4, 95% CI, 2.7-4.2, P < .001); elevated neutrophil-to-lymphocyte ratio was the strongest risk factor for hyperprogression (C-statistic = 0.62, P < .001). Conclusions This study presents first evidence for a markedly lower hyperprogression risk in advanced NSCLC patients treated with first-line ICI, particularly with chemoimmunotherapy, as compared to second- or later-line ICI treatment. This study evaluated hyperprogression risk with the use of immune checkpoint inhibitor (ICI) in the first-, second-, or later-line treatment of advanced non-small cell lung cancer, providing insight into hyperprogression risk with contemporary first-line ICI treatment.

• Publisher: Oxford University Press
• Subject: Cancer / Carcinoma, Non-Small-Cell Lung - pathology / Care and treatment / Chemotherapy / Development and progression / Diagnosis / Disease Progression / Dosage and administration / Humans / Immune Checkpoint Inhibitors - adverse effects / Immunotherapy / Lung Cancer / Lung cancer, Non-small cell / Lung Neoplasms - pathology / Patient outcomes / Progression-Free Survival